anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Major Depressive Disorder — Duloxetine Delayed-release Capsules should be administered at a total dose of 40 mg/day (given as 20 mg twice daily) to 60 mg/day (given either once daily or as 30 mg twice daily). For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg/day dose was shown to be effective, there is no evidence that doses greater than 60 mg/day confer any additional benefits. The safety of doses above 120 mg/day has not been adequately evaluated [see  Clinical Studies (14.1)] . 

Generalized Anxiety Disorder — For most patients, the recommended starting dose for Duloxetine Delayed-release Capsules is 60 mg administered once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg once daily dose was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit. Nevertheless, if a decision is made to increase the dose beyond 60 mg once daily, dose increases should be in increments of 30 mg once daily. The safety of doses above 120 mg once daily has not been adequately evaluated [see  Clinical Studies (14.2)] . 

Diabetic Peripheral Neuropathic Pain — The recommended dose for Duloxetine Delayed-release Capsules is 60 mg administered once daily. There is no evidence that doses higher than 60 mg confer additional significant benefit and the higher dose is clearly less well tolerated [see  Clinical Studies (14.3)] . For patients for whom tolerability is a concern, a lower starting dose may be considered. 

Since diabetes is frequently complicated by renal disease, a lower starting dose and gradual increase in dose should be considered for patients with renal impairment [see  Dosage and Administration (2.3),  Use in Specific Populations (8.10), and  Clinical Pharmacology (12.3)]. 

Chronic Musculoskeletal Pain — The recommended dose for Duloxetine Delayed-release Capsules is 60 mg once daily. Dosing may be started at 30 mg for one week, to allow patients to adjust to the medication before increasing to 60 mg once daily. There is no evidence that higher doses confer additional benefit, even in patients who do not respond to a 60 mg dose, and higher doses are associated with a higher rate of adverse reactions [see  Clinical Studies (14.5)] .
The invention relates novel pharmaceutical use of kaurane compounds of formula (I) in treating and preventing cardiac hypertrophy and myocardium remodeling. The said compounds also can significantly ameliorate pulmonary hypertension and preventing vascular hypertrophy. The said compounds can also be used to suppress fibrosis and to treat erection dysfunction, neurological degenerations and other related diseases by modulating cGMP or cAMP signal pathway and/or by reducing reactive oxygen species (ROS). Wherein R 1 : hydrogen, hydroxyl or alkoxy. R 2 : carboxyl, carboxylate, acyl halides, aldehyde, methyl-hydroxyl, and ester, acylamide, acyl or ether group hydrolysable to carboxyl. R 3 , R 4 , R 5 , R 6 , R 8 : independently, oxygen, hydroxyl, methyl-hydroxyl, and ester or alkoxymethyl group hydrolysable to methyl-hydroxyl. R 7 : methyl, hydroxyl, and ester or alkoxymethyl hydrolysable to methyl-hydroxyl. R 9 : methylene or oxygen.
Patients who underwent pancreaticoduodenectomy in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique. Most of the patients spent the first postoperative night in ICU where the monitoring of urine output and fluid balance are more specific than in a normal ward.
A recruitment maneuver will be performed in patients with decreased oxygen saturation due to atelectasis by applying 30 cm H2O positive pressure support for 30 seconds. The effect of the recruitment maneuver on intracranial pressure will be investigated by measuring the optic nerve sheath diameter with the help of ultrasonography before and after the recruitment maneuver.
BACKGROUND: The efficiency of mesenchymal stem cells (MSCs) in treating myocardial infarction (MI) remains inconsistent, which limits their therapeutic applications. Therefore, exploring the mechanism for the inconsistent efficacy of MSCs and identification the criteria for screening MSCs are important for improving the efficiency of MSCs.
METHODS: Mouse model after MI was utilized to test the role of MSCs from different donors and the functional subpopulation in improving cardiac function. Heterogeneity of MSCs was identified using single-cell RNA sequencing (scRNA-seq) of MSC-GY. GSEA and Scissor analyses were used to find the functional subpopulations of MSCs that promote angiogenesis. The role of functional subpopulations in promoting angiogenesis was verified by detecting the secretory proteins, the ratio of N-CADHERIN+/CD168- subpopulations in MSCs, and the tube formation, migration, and proliferation of HUVECs after treatment with conditional medium (CM) derived from different MSCs.
RESULTS: We found that umbilical cord-derived MSCs (UC-MSCs) from different donors have varied therapeutic efficacy in MI mice and UC-MSCs with higher therapeutic effectiveness exhibited the most potent pro-angiogenic effects by secreting elevated levels of angiogenesis-related proteins, such as MYDGF, VEGFA, and FGF2. ScRNA-seq of 10,463 UC-MSCs revealed that the N-CADHERIN+/CD168- subpopulation was closely associated with pro-angiogenic effects, and the ratio of this cell subpopulation was positively correlated with the angiogenic potential of MSCs. We also found that the N-CADHERIN+/CD168- subpopulation was the functional subpopulation of MSCs in improving cardiac function of MI mice.
CONCLUSIONS: Our study identified that the N-CADHERIN+/CD168- subpopulation was the functional subpopulation of MSCs in treating MI, which was essential for the development and utilization of MSCs in MI treatment.
FIELD: medicine, pharmaceutics. SUBSTANCE: soybean extract contains about 0.6- 1.5 weight portions of group B soybean saponins at the rate of 1 weight portion of glycoside isoflavones contained in an extract, at least, at the amount of 13%. Extraction of fat-free soya beans or meal is conducted with aliphatic alcohols or their aqueous mixtures at reciprocal ratio of 3:2 - 2: 3. Extract is concentrated, purified, extracted either with aliphatic hydrocarbons nonmiscible with water or alcohols nonmiscible with water. Extract is concentrated and dried. Pharmaceutical composition containing soybean extract to treat and prevent pre- and postclimacteric symptoms, alcoholism, mammary gland and prostatic cancers is, also, suggested. EFFECT: higher efficiency of medicinal preparations. 11 cl, 5 ex, 3 tbl, 1 dwg
Computed tomography (CT) imaging is a vital tool for the diagnosis and assessment of lung adenocarcinoma, and using CT images to predict the recurrence-free survival (RFS) of lung adenocarcinoma patients post-surgery is of paramount importance in tailoring postoperative treatment plans. Addressing the challenging task of accurate RFS prediction using CT images, this paper introduces an innovative approach based on self-supervised pre-training and multi-task learning. We employed a self-supervised learning strategy known as "image transformation to image restoration" to pretrain a 3D-UNet network on publicly available lung CT datasets to extract generic visual features from lung images. Subsequently, we enhanced the network's feature extraction capability through multi-task learning involving segmentation and classification tasks, guiding the network to extract image features relevant to RFS. Additionally, we designed a multi-scale feature aggregation module to comprehensively amalgamate multi-scale image features, and ultimately predicted the RFS risk score for lung adenocarcinoma with the aid of a feed-forward neural network. The predictive performance of the proposed method was assessed by ten-fold cross-validation. The results showed that the consistency index (C-index) of the proposed method for predicting RFS and the area under curve (AUC) for predicting whether recurrence occurs within three years reached 0.691 ± 0.076 and 0.707 ± 0.082, respectively, and the predictive performance was superior to that of existing methods. This study confirms that the proposed method has the potential of RFS prediction in lung adenocarcinoma patients, which is expected to provide a reliable basis for the development of individualized treatment plans.
This is a single-centre, single-arm open-label proof-of-concept study to analyze the imaging (DCE-CT,CEUS and Quantitative US) effects of neoadjuvant bevacizumab and SBRT on colorectal metastases to the liver. Patients will receive 2 doses of bevacizumab 5mg/kg IV prior to SBRT. The second dose of bevacizumab will be given 2 weeks after the first dose of bevacizumab and within 48 hours of starting the first dose of SBRT. The SBRT prescription dose will be up to 60 Gy in 6 fractions, delivered on alternating weekdays for 2 weeks. Total SBRT dose will be determined by size of target lesion, liver sparing and organs-at-risk dose constraints. DCE-CT, CEUS and Quantitative US will be performed within 7 days prior to the first dose of bevacizumab, after the second dose of bevacizumab and within 7 days of completing SBRT.
A prospective, controlled and comparative clinical trial before CE marking of a new ECG monitoring system CardioSenseSystem. The study population will consist of sixty (60) adult subjects requiring ECG and that are fulfilling the eligibility criteria for study participation. The subjects will be monitored by both the investigational device and the control device for measuring data loss, management time and alarm function up to 24 hours. The duration of the study is estimated to 4 months.

CardioSenseSystem is designed to provide wireless high-quality ECG monitoring. The system developed by Novosense AB consists of three components: the CardioPatch, the Novosense Base Station and the Back-End System. The CardioPatch is a wireless sensor capable to record and transmit ECG data. The CardioPatch send ECG data to the Novosense Base Station, which is the receiving unit. The Back-End System is used for presentation, storage and processing of ECG information. The CardioPatch sensor is applied to the body with an adhesive in the same way as a traditional ECG electrode. In contrast, the CardioPatch is a fully integrated unit containing electrodes, ECG amplifier and a radio transmitter. Novosense's wireless ECG sensors, CardioPatch, transmits the ECG signal 24 hours to the Novosense Base Station receiver.
NEW MATERIAL:The phosphoric acid diester of formula I (X is H or halogen) or its salt. EXAMPLE:DL-alpha-tocopherol 5-bromouridine phosphoric acid diester. USE:An anti-inflammatory agent and carcinostatic agent. PREPARATION:alpha-Tocopherol of formula II is made to react with a halophosphoric acid esterifying agent (preferably phosphorous oxytrichloride or phosphorus oxytribromide). The resultant compound of formula III is reacted with uridine having protective groups on 2'- and 3'-OH groups or its 5-halogen substituted compound. The above protective groups are removed from the reaction product to obtain the objective compound.
Participants will receive 20 virtual visits with a trained Veteran peer health coach over 12 months. Coaches will provide participants with brief health education, assist with goal setting and problem solving, enhance social support, and link participants to VA and community resources.
Disclosed and described systems, methods, and apparatus provided facilitate analysis, presentation, and comparison of clinical information. An example system includes a processor configured to provide a patient library interface. The interface displays a plurality of events along a patient timeline and a list of items for comparison to a clinical scenario. The scenario is specified in an interface configuration to trigger collection of the list of comparison items. The processor receives and adds items to the list based on a relevancy analysis of each item to the clinical scenario. The processor facilitates feedback to add, remove, and rate relevance of item(s) in the list. The processor displays item(s) from the list in conjunction with documentation from the clinical scenario and facilitates user interaction with the item(s) and documentation. The processor updates a data source based on the user feedback and user interaction.
Dexmedetomidine hydrochloride injection is indicated for short-term intravenous sedation. Dosage must be individualized and titrated to the desired clinical effect. Blood pressure, heart rate and oxygen levels will be monitored both continuously during the infusion of dexmedetomidine hydrochloride and as clinically appropriate after discontinuation.

  * When dexmedetomidine hydrochloride is infused for more than 6 hours, patients should be informed to report nervousness, agitation, and headaches that may occur for up to 48 hours.
  * Additionally, patients should be informed to report symptoms that may occur within 48 hours after the administration of dexmedetomidine hydrochloride such as: weakness, confusion, excessive sweating, weight loss, abdominal pain, salt cravings, diarrhea, constipation, dizziness or light-headedness.
  * Advise breastfeeding mothers who were exposed to dexmedetomidine hydrochloride to monitor breastfed neonates for irritability [see Use in Specific Populations (8.2)].
The recommended initial dose of AVAPRO (irbesartan) is 150 mg once daily. Patients requiring further reduction in blood pressure should be titrated to 300 mg once daily.

A low dose of a diuretic may be added, if blood pressure is not controlled by AVAPRO alone. Hydrochlorothiazide has been shown to have an additive effect (see CLINICAL PHARMACOLOGY: Clinical Studies). Patients not adequately treated by the maximum dose of 300 mg once daily are unlikely to derive additional benefit from a higher dose or twice-daily dosing.

No dosage adjustment is necessary in elderly patients, or in patients with hepatic impairment or mild to severe renal impairment.
PROBLEM TO BE SOLVED: To provide compositions and methods for modulating a kinase cascade.SOLUTION: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (KX2-391), and methods for modulating one or more components of a kinase cascade. Compounds of the invention are useful in modulation of a component of a kinase signaling cascade. Some compounds may be useful in modulation of two or more components of a kinase signaling cascade. The compounds of the present invention are useful as pharmaceutical agents. The compounds of the invention may be useful for modulating regulation of a kinase which may be involved in a normal cellular signal transduction pathway (e.g., cell growth, differentiation, survival, adhesion, migration, etc.), or a kinase involved in a disease or disorder.SELECTED DRAWING: None
This study was designed as a single-centre, retrospective, observational study including all lung transplants between January 2020 and December 2022 within the Prague Lung Transplant Program Motol University Hospital. A total of 141 patients were transplanted during the study period. The exclusion criteria were lung transplant without intraoperative ECMO support, block heart-lung transplantation, ECMO bridge to lung transplant and planned postoperative ECMO. The inclusion criteria were lung transplantation performed with intraoperative ECMO support, central ECMO cannulation, and successful ECMO support termination at the end of the surgery. According to the study inclusion criteria, only lung transplants under intraoperative central ECMO cannulation with successful ECMO weaning were included. A total of 109 patients fulfilled the inclusion criteria. Thirty-two patients were excluded based on the following exclusion criteria: heart-lung transplant (HLTx) n=4, ECMO bridge n=4, transplantation (Tx) without ECMO n=8, and planned prolonged ECMO n=16. UFH was used for ECMO anticoagulation in all patients. The subjects were divided into two groups according to the UFH dose during the entire surgical procedure. In the first group, the dose of UFH was below or equal to 60 IU/kg/surgery. In the second group, the dose of UFH was above 60 IU/kg/surgery. A cut-off value of 60 IU/kg was determined according to the available literature review. Values ≤ 60 IU/kg/surgery were considered relatively lower doses, and values \> 60 IU/kg/surgery were considered higher doses of UFH. The UFH effect was monitored by activated clotting time (ACT) values. The intraoperative haemoglobin level target for red blood cells (RBCs) substitution was 100 g/l. The parameters that will be monitored intraoperatively in both groups are the total blood loss in millilitres and related to the patient's weight during the operation, the total amount of UFH administered to the patient during the procedure in international units (IU) and related to the patient's weight, and the consumption of blood derivatives during surgery such as red blood cells, fresh frozen plasma (FFP) and platelets. In both groups, ACT values will be monitored after the administration of UFH before ECMO cannulation. In the postoperative period, the investigators will monitor the development of hemothorax requiring surgical revision. The investigators consider surgical revision for hemothorax to be a significant bleeding complication. 30-day and 90-day mortality, ECMO- and patient-related thrombotic complications will be assessed.
Physiological saline solution (PSS). Every 15-minutes, the PSS will be flushed and fresh PSS will be added.
PURPOSE:To obtain the new protein derived from human plasma, having a specific amino acid sequence, presenting such opsonin activity as to be subject to oligophagous activity by oligophagous cells like neutrophiles through its sticking to pathogenic microbes, thus useful as a preventive/therapeutic agent for infectious diseases. CONSTITUTION:Calcium chloride is added to citric acid-added human plasma to effect coagulation followed by filtration and centrifugal separation to separate serum. Polyethylene glycol is then added to the serum and the resultant precipitate is centrifuged and then dissolved in a buffer solution. The resultant solution is passed through an yeast-immobilized mannan column which is then washed and treated with a mannose- contg. buffer solution, and the adsorbed substance is eluted using a 0.15 M N- acetylglucosamine-contg. buffer solution, and the impurities in the resultant elute is removed to purify the adsorbed substance, thus obtaining the objective new protein containing an amino acid sequence of formula I and having the following characteristics: molecular weight determined by SDS-polyacrylamide gel electrophoresis under reduction: about 35kDa; having amino acid sequence of formula II at the N- terminal; and, presenting opsonin activity. This protein is useful as, e.g. a preventive/ therapeutic agent for infectious diseases.
Provided are materials including cell proliferation properties. The materials may include a polymer having incorporated therein a synergistic combination of at least two metal oxide powders, including a mixed oxidation state oxide of a first metal and a single oxidation state oxide of a second metal. The mixed oxidation state oxide may constitute from about 25% wt. to about 75% wt. of the total weight of the synergistic combination of the at least two metal oxide powders. The powders may be incorporated substantially uniformly within the polymer. The ions of the metal powders may be in ionic contact upon exposure of the material to moisture. Further provided are methods for the preparation of the materials and uses thereof, including in skin regeneration processes and cosmetic applications.
Oxycodone hydrochloride is extensively metabolized to noroxycodone, oxymorphone, noroxymorphone, and their glucuronides. The major circulating metabolite is noroxycodone. Noroxycodone is reported to be a considerably weaker analgesic than oxycodone. Oxymorphone, although possessing analgesic activity, is present in the plasma only in low concentrations. The correlation between oxymorphone concentrations and opioid effects was much less than that seen with oxycodone plasma concentrations. The analgesic activity profile of other metabolites is not known. 

CYP3A mediated N-demethylation (to noroxycodone) is the primary metabolic pathway of oxycodone with a lower contribution from CYP2D6 mediated O-demethylation (to oxymorphone). Therefore, the formation of these and related metabolites can, in theory, be affected by other drugs (see Drug-Drug Interactions).
Teratogenic studies were performed in pregnant rats and rabbits with scopolamine hydrobromide administered by daily intravenous injection. No adverse effects were recorded in rats. Scopolamine hydrobromide has been shown to have a marginal embryotoxic effect in rabbits when administered by daily intravenous injection at doses producing plasma levels approximately 100 times the level achieved in humans using a transdermal system. During a clinical study among women undergoing cesarean section treated with Transderm Scōp in conjunction with epidural anesthesia and opiate analgesia, no evidence of CNS depression was found in the newborns. There are no other adequate and well-controlled studies in pregnant women. Other than in the adjunctive use for delivery by cesarean section, Transderm Scōp should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz. The intensities of FSWT were 0.10 mJ/mm2.
The objective of this study was to investigate the effects of exposure to rotenone, sleep deprivation, and the epidermal growth factor receptor (EGFR) inhibitor on the locomotor activity of zebrafish larvae. Observations were conducted on control groups, sleep-deprived groups without interventions, groups treated with rotenone or the EGFR inhibitor alone, and also groups with combined exposures. The results showed that sleep deprivation alone led to a decrease of speed of the locomotor activity compared to the control groups. The treatment with rotenone alone resulted in varied effects on the locomotor activity. However, a combined exposure to rotenone and sleep deprivation further reduced the locomotor activity compared to the control and rotenone-treated groups. The groups treated with the EGFR inhibitor alone exhibited variable effects on the locomotor activity. Furthermore, the combined exposure to the EGFR inhibitor and sleep deprivation resulted in diverse changes in the locomotor activity. However, the combined treatment with rotenone and the EGFR inhibitor produced complex alterations in the locomotor activity. These findings demonstrate the distinct effects of exposure to rotenone, sleep deprivation, and the EGFR inhibitor on the locomotor activity of zebrafish larvae. The interaction between these factors further modulates locomotor activity, suggesting a potential interplay between the EGFR system, sleep regulation, and the dopaminergic system. Understanding the relationship between the EGFR system, sleep regulation, and neurological regulation may contribute to the development of therapeutic strategies to address such issues as sleep disorders and neurodegenerative conditions.
Patients were started on Carrelizumab in combination with Apatinib 2-3 weeks after cryoablation. Karelizumab 200 mg, q3w, and Apatinib 250 mg, qd. Every 3 weeks is a treatment cycle.
Patients receive abemaciclib PO Q12H. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.